Drugs for serious illnesses should qualify for accelerated approval based on biomarkers before patient benefit is proven

FDA approvals, clinical trial design, psychedelic drug policy, compounding pharmacy regulation, and drug scheduling.

Ethical issues in medicine and biomedical research: gene editing, reproductive technology, end-of-life care, organ markets, performance enhancement, and dual-use research.

Monitoring and prevention of adverse effects from medications.

Whistleblowing, proximity to power, government cover-ups, research funding conflicts, and race-corrected medical algorithms.

Substances used for treatment, prevention, or diagnosis of disease.